Clinical & Experimental Cardiology
Open Access

Intracoronary Gene Therapy for Endothelial Rescue in Refractory Ischemia

Angela Sajjadi^{* *}Correspondence: Angela Sajjadi, Department of Cardiology, University of Chicago, Chicago, USA, Email:

Author info »

Description

Refractory ischemia, defined as persistent myocardial ischemia despite optimal medical therapy and revascularization attempts, represents a significant clinical challenge in cardiology. Patients suffering from refractory ischemia often experience angina, exercise intolerance, and an increased risk of adverse cardiovascular events, including myocardial infarction and heart failure. Conventional treatment strategies, such as percutaneous coronary intervention and coronary artery bypass grafting, are often limited by anatomical constraints, diffuse coronary disease, or comorbid conditions that preclude further intervention. Moreover, pharmacologic approaches may be insufficient to restore adequate perfusion or promote long-term vascular health in these patients. In this context, intracoronary gene therapy has emerged as a promising strategy to rescue endothelial function, stimulate neovascularization, and improve myocardial perfusion by delivering targeted genetic material directly to the coronary vasculature.

Endothelial dysfunction is a central pathophysiological mechanism in refractory ischemia. The endothelium plays a critical role in regulating vascular tone, platelet aggregation, inflammation, and angiogenesis. Impaired endothelial signaling reduces nitric oxide bioavailability, promotes vasoconstriction, and enhances oxidative stress, all of which contribute to persistent myocardial ischemia and adverse remodeling. Gene therapy offers the potential to address these underlying molecular defects by introducing genes that encode for angiogenic factors, anti-apoptotic proteins, or enzymes that enhance endothelial function. Unlike systemic pharmacologic therapy, intracoronary gene delivery allows for localized, highconcentration treatment with minimal off-target effects, thereby increasing efficacy and safety.

Several therapeutic genes have been investigated for endothelial rescue in refractory ischemia. Vascular Endothelial Growth Factor (VEGF) is among the most extensively studied, owing to its potent angiogenic properties. Intracoronary delivery of VEGF genes has been shown to stimulate endothelial proliferation, promote the formation of new capillaries, and enhance collateral vessel development in ischemic myocardium. Similarly, Fibroblast Growth Factor (FGF) genes have been employed to activate angiogenic pathways and improve microvascular perfusion. Other promising candidates include nitric oxide synthase genes, which restore nitric oxide production and improve vasodilation, and anti-apoptotic genes that protect endothelial cells from oxidative stress-induced injury. The choice of gene depends on the underlying pathophysiology of the ischemia, the extent of endothelial damage, and the desired therapeutic outcome.

The method of delivery is a critical determinant of the success of intracoronary gene therapy. Catheter-based systems enable the direct infusion of viral or non-viral vectors into the coronary arteries, often under conditions that enhance transfection efficiency, such as transient occlusion or high-pressure injection. Adenoviral vectors have been widely used due to their high transduction efficiency and transient gene expression, which is sufficient for stimulating angiogenesis while minimizing longterm immunogenicity. Adeno-associated viral vectors provide longer-lasting gene expression with lower immunogenic risk, making them attractive for chronic endothelial support. Nonviral delivery systems, such as plasmid DNA or nanoparticle carriers, offer the advantage of reduced immune responses and simplified manufacturing, although they often require optimization to achieve efficient uptake by endothelial cells. Advanced delivery techniques, including endothelial-targeted nanoparticles and ligand-modified vectors, are under investigation to enhance selectivity and minimize off-target effects.

Preclinical studies have demonstrated the potential of intracoronary gene therapy for endothelial rescue in models of refractory ischemia. Animal experiments have shown that local delivery of VEGF or FGF genes can increase capillary density, improve myocardial perfusion, and enhance left ventricular function in ischemic regions. Endothelial-specific gene expression has been observed to reduce oxidative stress markers and improve nitric oxide availability, suggesting restoration of endothelial homeostasis. Importantly, these studies have also highlighted the safety profile of localized gene therapy, with minimal systemic toxicity and limited inflammatory response. The success of these preclinical studies has provided a rationale for clinical translation and the design of early-phase human trials. 

Clinical trials of intracoronary gene therapy in patients with refractory angina have shown encouraging results. Phase I and II studies of VEGF and FGF gene delivery have reported improvements in exercise tolerance, angina frequency, and perfusion as assessed by imaging modalities such as singlephoton emission computed tomography and cardiac Magnetic Resonance Imaging (MRI). Although the magnitude of effect varies across studies, these trials have consistently demonstrated that localized gene therapy can induce biologically meaningful angiogenic responses in patients who have exhausted conventional treatment options. Long-term follow-up has indicated a favorable safety profile, with few reports of adverse events related to vector delivery, arrhythmias, or systemic toxicity. These findings support the feasibility of intracoronary gene therapy as an adjunct or alternative to traditional revascularization strategies in refractory ischemia.

Conclusion

Intracoronary gene therapy represents a promising frontier in the management of refractory ischemia, offering the potential to rescue endothelial function, stimulate neovascularization, and improve myocardial perfusion in patients unresponsive to conventional therapy. By directly targeting the molecular mechanisms underlying endothelial dysfunction, this approach provides a mechanistically rational strategy to restore vascular homeostasis and promote cardiac regeneration. Preclinical and early clinical studies have demonstrated feasibility, safety, and biologically meaningful improvements in perfusion and function. Ongoing research aimed at optimizing vector design, delivery methods, and combinatorial approaches is likely to enhance the efficacy and durability of this therapy. As our understanding of endothelial biology and gene therapy technology advances, intracoronary gene therapy has the potential to become a transformative treatment modality for patients with refractory ischemia, offering hope to those for whom traditional interventions have proven inadequate.